Clinical Trial Update: A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of adding ipatasertib to paclitaxel in advanced breast cancer with HR/ HER2 receptor status unspecified in snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2021-01-11